Free Trial
NASDAQ:CADL

Candel Therapeutics (CADL) Stock Price, News & Analysis

Candel Therapeutics logo
$5.10 +0.11 (+2.20%)
Closing price 07/3/2025 03:54 PM Eastern
Extended Trading
$5.10 0.00 (0.00%)
As of 07/3/2025 04:18 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

About Candel Therapeutics Stock (NASDAQ:CADL)

Key Stats

Today's Range
$4.89
$5.12
50-Day Range
$4.52
$6.04
52-Week Range
$3.79
$14.60
Volume
619,068 shs
Average Volume
1.48 million shs
Market Capitalization
$255.51 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$22.00
Consensus Rating
Buy

Company Overview

Candel Therapeutics Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
49th Percentile Overall Score

CADL MarketRank™: 

Candel Therapeutics scored higher than 49% of companies evaluated by MarketBeat, and ranked 539th out of 929 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Candel Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 4 buy ratings, no hold ratings, and no sell ratings.

  • Amount of Analyst Coverage

    Candel Therapeutics has only been the subject of 1 research reports in the past 90 days.

  • Read more about Candel Therapeutics' stock forecast and price target.
  • Earnings Growth

    Earnings for Candel Therapeutics are expected to grow in the coming year, from ($1.47) to ($1.15) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Candel Therapeutics is -3.81, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Candel Therapeutics is -3.81, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    Candel Therapeutics has a P/B Ratio of 3.62. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

  • Read more about Candel Therapeutics' valuation and earnings.
  • Percentage of Shares Shorted

    17.18% of the float of Candel Therapeutics has been sold short.
  • Short Interest Ratio / Days to Cover

    Candel Therapeutics has a short interest ratio ("days to cover") of 6.4.
  • Change versus previous month

    Short interest in Candel Therapeutics has recently increased by 6.28%, indicating that investor sentiment is decreasing significantly.
  • Dividend Yield

    Candel Therapeutics does not currently pay a dividend.

  • Dividend Growth

    Candel Therapeutics does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    17.18% of the float of Candel Therapeutics has been sold short.
  • Short Interest Ratio / Days to Cover

    Candel Therapeutics has a short interest ratio ("days to cover") of 6.4.
  • Change versus previous month

    Short interest in Candel Therapeutics has recently increased by 6.28%, indicating that investor sentiment is decreasing significantly.
  • News Sentiment

    Candel Therapeutics has a news sentiment score of 0.88. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.58 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 14 news articles for Candel Therapeutics this week, compared to 3 articles on an average week.
  • Search Interest

    21 people have searched for CADL on MarketBeat in the last 30 days. This is an increase of 320% compared to the previous 30 days.
  • MarketBeat Follows

    Only 1 people have added Candel Therapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of -80% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Candel Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $3,936.00 in company stock.

  • Percentage Held by Insiders

    16.60% of the stock of Candel Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.

  • Percentage Held by Institutions

    Only 13.93% of the stock of Candel Therapeutics is held by institutions.

  • Read more about Candel Therapeutics' insider trading history.
Receive CADL Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Candel Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

CADL Stock News Headlines

What is HC Wainwright's Estimate for CADL Q2 Earnings?
What is HC Wainwright's Estimate for CADL Q3 Earnings?
Elon’s BIGGEST warning yet?
Tesla's About to Prove Everyone Wrong... Again Back in 2018, when Jeff Brown told everyone to buy Tesla… The "experts" said Elon was finished and Tesla was headed for bankruptcy. Now they're saying the same thing, but Jeff has uncovered Tesla's next breakthrough.
HC Wainwright Upgrades Candel Therapeutics (NASDAQ:CADL) to Buy
CADL - Candel Therapeutics Inc Ownership - Morningstar
See More Headlines

CADL Stock Analysis - Frequently Asked Questions

Candel Therapeutics' stock was trading at $8.68 on January 1st, 2025. Since then, CADL shares have decreased by 41.2% and is now trading at $5.10.

Candel Therapeutics, Inc. (NASDAQ:CADL) issued its quarterly earnings results on Tuesday, May, 13th. The company reported $0.13 EPS for the quarter, beating analysts' consensus estimates of ($0.24) by $0.37.

Candel Therapeutics (CADL) raised $72 million in an initial public offering on Tuesday, July 27th 2021. The company issued 9,000,000 shares at $8.00 per share. Jefferies, Credit Suisse, BMO Capital Markets and UBS Investment Bank served as the underwriters for the IPO.

Shares of CADL stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Candel Therapeutics investors own include Advanced Micro Devices (AMD), Netflix (NFLX), NVIDIA (NVDA), Tesla (TSLA), Alphabet (GOOG), Meta Platforms (META) and Visa (V).

Company Calendar

Last Earnings
5/13/2025
Today
7/05/2025
Next Earnings (Estimated)
8/12/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
MED - BIOMED/GENE
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:CADL
Fax
N/A
Employees
60
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$22.00
High Stock Price Target
$25.00
Low Stock Price Target
$15.00
Potential Upside/Downside
+331.4%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
4 Analysts

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$55.18 million
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
$120 thousand
Price / Cash Flow
N/A
Book Value
$1.41 per share
Price / Book
3.62

Miscellaneous

Free Float
41,786,000
Market Cap
$255.51 million
Optionable
Optionable
Beta
-0.91
The 10 Best AI Stocks to Own in 2025 Cover

Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.

Get This Free Report

This page (NASDAQ:CADL) was last updated on 7/5/2025 by MarketBeat.com Staff
From Our Partners